Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase NA 5Phase 3 4Phase 1 3Phase 1/2 2Phase EARLY_PHASE1 1

Status

Completed 29Terminated 12Active not recruiting 12Unknown 7Recruiting 7Withdrawn 4Not yet recruiting 3Enrolling by invitation 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 2Head & Neck 1Gastrointestinal 1

Conditions

Breast Neoplasms 25Neoplasms 19Prostatic Neoplasms 15Carcinoma, Non-Small-Cell Lung 15Carcinoma, Hepatocellular 10Urinary Bladder Neoplasms 8Ovarian Neoplasms 8Head and Neck Neoplasms 8Pain 7Lung Neoplasms 7Leukemia, Myeloid, Acute 7Squamous Cell Carcinoma of Head and Neck 6Neoplasm Metastasis 6Lymphoma, Follicular 6Leukemia 6Uterine Cervical Neoplasms 5Stomach Neoplasms 5Recurrence 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Non-Muscle Invasive Bladder Neoplasms 5Brain Neoplasms 5Small Cell Lung Carcinoma 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Lymphoma 4Leiomyoma 4Carcinoma 4Urologic Neoplasms 3Urogenital Neoplasms 3Papillomavirus Infections 3

Interventions

trifluridine tipiracil drug combination 1palladium-bacteriopheophorbide 1padeliporfin 1nimotuzumab 1futuximab 1Radiotherapy 1Mitomycin 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Withdrawn × Carcinoma × Clear all
NCT01345084 2025-03-28

NICAP

Eurofarma Laboratorios S.A.

Phase 3 Withdrawn
Head & Neck

Carcinoma, Head and Neck Neoplasms

NCT04225299 2020-11-13

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

Steba Biotech S.A.

Phase 3 Withdrawn
Genitourinary

Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT04006691 2020-05-07

Retreatment

UroGen Pharma Ltd.

Phase 3 Withdrawn
Genitourinary

Carcinoma, Carcinoma, Transitional Cell

NCT03717038 2019-02-04

Sym004 Versus TAS-102 in Patients With mCRC

Symphogen A/S

Phase 3 Withdrawn
Gastrointestinal

Carcinoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡